Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Regeneron And Teva's Fasinumab Crosses One Threshold; More Remain

Executive Summary

The companies reported positive Phase III data testing the nerve growth factor inhibitor in patients with chronic pain, but the efficacy appears modest and safety will remain a question until long-term Phase III data read out. The companies are focused on a lower 1 mg dose.

Advertisement

Related Content

Lilly/Pfizer’s Tanezumab Safety Takes A Hit With Latest Phase III Results
Tanezumab Dances Through Back Pain Studies With “Acceptable” Safety Answers
Pfizer, Lilly Weigh In On Dosing And Safety Of Non-Opioid Pain Drug Tanezumab
10 Things For Pfizer's New CEO To Worry About
Handful Of Drugs Aim To Modify Osteoarthritis
Pfizer/Lilly's Tanezumab Reduces Osteoarthritis Pain, But Is It Safe?
Regeneron Partners NGF Antibody With Teva To Mitigate Risks

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123706

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel